Merck KGaA Campral alcoholism treatment is in Phase III U.S. studies, firm tells UBS conference.
MERCK KGaA ALCOHOLISM THERAPY CAMPRAL ON TRACK FOR 2000 LAUNCH in the U.S., Merck KGaA Chairman Hans Langmann told a UBS Securities life sciences conference in London April 16. Campral (acamprosate) is in Phase III trials in the U.S. Langmann maintained Campral has "blockbuster potential." The drug is marketed in seven European countries, with launches in three more expected this year, Langmann noted.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth